

downloaded: 12.5.2024

source: https://doi.org/10.48350/190336 |

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

1 Conflicts of interest:

- 2 MF received speaker and consultation fees from Pfizer and Boehringer Ingelheim Poland.
- 3 LR has received speaker and consulting fees from Abbott and Medtronic and a research grant to the

4 institution from Medtronic.

- 5 CdA received compensation for teaching purposes and proctoring from Medtronic, Abbott,
- 6 Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical, Daiichi Sankyo.
- GC has received honoraria fees from Biosense Webster and Boston Scientific, research grants from
 Boston Scientific.
- 9 SB is consultant for Medtronic, Boston Scientific, Microport, and Zoll.
- 10 JC received speaker, consultation, teaching and proctoring honoraria from Medtronic, Boston
- 11 Scientific and Biosense Webster
- 12

13 **Funding:** none.

14

15 Abstract

Introduction: Limited data are available regarding venous thromboembolism (VTE), specifically deep vein thrombosis (DVT) and pulmonary embolism (PE), following right-sided ablations and electrophysiological (EP) studies. Compared to left-sided procedures, no guidelines on antithrombotic management strategies for the prevention of DVT and PE are available. The main purpose of the present European Heart Rhythm Association (EHRA) survey is to report the current management of right-sided EP procedures, focusing on anticoagulation and prevention of VTE.

Methods and Results: An online survey was conducted using the EHRA infrastructure. A total of
244 participants answered a 19-items questionnaire on the periprocedural management of EP
studies and right-sided catheter ablations.

The right femoral vein is the most common access for EP studies and right-sided procedures. An ultrasound-guided approach is employed by more than 2/3 of respondents. Intravenous heparin is not commonly given by the majority of participants. About 1/3 of participants (34%) routinely prescribe VTE prophylaxis during (mostly aspirin and low molecular weight heparin) and 1/4 of respondents (25%) commonly prescribe VTE prophylaxis after discharge (mostly aspirin). Of note, respectively 13% and 9% of participants observed at least one DVT and one PE related to right sided ablation or EP study within the last year in their center.

3 Conclusions: The present survey shows that only a minority of operators routinely gives
4 intraprocedural intravenous heparin and prescribes VTE prophylaxis after right-sided EP
5 procedures. Compared to left-sided procedures like AF ablation, there are no consistent systematic
6 antithrombotic management strategies.

7

8 Keywords: catheter ablation; electrophysiological study; right-sided ablations; anticoagulation.

9

10 Condensed Abstract

11 The European Heart Rhythm Association (EHRA) investigated with an online survey the current 12 peri-procedural management of electrophysiological studies and right-sided ablations in terms of 13 anticoagulation and venous thromboembolism prevention.

14

15 What's new?

- The echo-guided is currently adopted in a routine way by only one third of respondents
 (37%);
- 18 The "heparin bridging" in patients on VKA is still adopted by a significant amount of
 19 physicians (29%);
- Intravenous heparin is adopted by a smaller but not negligible amount of European
 electrophysiologists during EP studies (28%) and right-sided ablation (37%);
- VTE prophylaxis is on average- adopted by 1 operator out of 4 after the discharge (25%),
 and the type of VTE prophylaxis is heterogeneous;
- Among operators who prescribe VTE prophylaxis, the majority (71%) give aspirin;
- 25 No significant differences were found in anticoagulation strategies neither between Northern
- and Southern Europe nor between fully trained EPS and senior/junior EP fellows

1 Introduction

Femoral venous access is commonly used for all right-sided ablation procedures and for diagnostic 2 electrophysiological (EP) studies. Limited data are available about venous thromboembolism 3 (VTE), specifically deep venous thrombosis (DVT) and pulmonary embolism (PE), following right-4 sided ablations and EP studies¹⁻¹³. In left-sided ablation procedures, especially pulmonary vein 5 6 isolation, the peri-procedural approach is well standardized and homogenous throughout most of the centers and guidelines exist¹⁴⁻¹⁵. Conversely, for right-sided procedures there is no clear guidance 7 from guidelines and no broadly accepted or standardized approach/workflow. Symptomatic DVT 8 9 and PE following right-sided EP procedures are globally reported in 0.5-0.8% of patients¹. Although venous thromboembolism is considered a rare event, it might potentially lead to severe 10 consequences. The main purpose of this European Heart Rhythm Association (EHRA) survey was 11 to investigate the management of right-sided ablations, especially in terms of anticoagulation and 12 prevention of VTE, among cardiac electrophysiologists. 13

14 Methods

This physician-based survey was promoted and disseminated by EHRA. An online questionnaire,
consisting of 19 multiple-choice questions, was developed, amended and validated by the Scientific
Initiative Committee (SIC).

The questionnaire was distributed through official EHRA channels (EHRA newsletters, Scientific Research Network members, and national electrophysiology working groups) and social media platforms. It was active between 18 October and 21 November 2022. All cardiologists working in the field of Electrophysiology, from junior cardiac electrophysiology fellows to senior fellows until to fully trained cardiac electrophysiologists, were deemed to be eligible to participate in the survey.

In detail, the questionnaire was created by the promotor and then shared with the members of the working group; then, the questionnaire was shared, discussed and debated with all members of the SIC Committee. The specific queries included in the questionnaire are shown in Supplementary material online. Results were collected anonymously in compliance with the European General Data Protection
 Regulation (GDPR) 2016/679.

3 Data were analyzed using descriptive statistical methods. Categorical variables are presented
4 numerically with absolute percentages (%).

5 Descriptive statistics

Continuous variables are expressed as mean ± SD or median and range as appropriate. Categorical
variables are expressed as absolute and relative frequencies. Comparisons of continuous variables
were done with a Student's t-test or the Mann-Whitney U-test as appropriate. The Chi-square test or
the Fisher's exact test was used to compare categorical variables as appropriate. A 2-tailed
probability value of <0.05 was deemed significant. Statistical analyses were conducted using the
SPSS software (SPSS v20, Chicago, IL, USA).

12

13 **Results**

From 18 October to 21 November 2022, a total of 244 respondents from 33 European countries 14 (Armenia, Austria, Belgium, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, 15 Estonia, France, Georgia, Germany, Greece, Hungary, Iceland, Italy, Latvia, Malta, The 16 Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, 17 Sweden, Switzerland, Turkey, Ukraine, United Kingdom) participated in the survey (Figure 1). 18 Respondents from Italy and Germany most frequently participated in the survey (respectively 24% 19 20 and 16% of the overall participants) followed by respondents from Spain (6%), Croatia (5%), Belgium (4%), Greece (4%) and United Kingdom (4%). The average age of the responders was $43\pm$ 21 9 years. The majority of respondents were male (78%). 22

The majority of participants worked in university hospitals (56%). The remaining participants worked in specialized public cardiology centers (19%), public community hospitals (14%) and private hospitals/clinics (11%). Most of the survey respondents were fully trained cardiac electrophysiologists (73%), followed by junior cardiac electrophysiology fellows (18%) and senior cardiac electrophysiology fellows (9%). The mean number of years of training among participants
 was 11±8 years (median 10 years, interquartile range 5 to 15 years).

The mean volume of right-sided EP procedures performed at the centers of the participants was 166±110/year (median 115/year and interquartile range 100 to 215/year). In details, only 4% of the participants performed less than 50 right-sided procedures per year at their centers; 20% of the respondents worked in centers performing 50-100 right-sided procedures per year; 32% of the physicians declared to perform between 100 and 150 procedures per year and 10% stated to perform between 150 and 200 procedures. The remaining 34% of participants were active in centers performing more than 200 right-sided EP procedures per year.

Fifty-four percent of respondents stated that, in their centers, they kept a systematic, institutional
reporting system used for the collection and assessment of EP procedure-related complications. The
median response rate for each question was 80.3% [IR 76.2%; 82.3%].

13 Venous access and procedural approach

Most of the respondents declared to use 2 or 3 catheters (respectively, 46% and 44%) for performing EP studies and predominantly 3 catheters for AVNRT, right accessory pathway, and right AT ablation (respectively 55%, 57% and 56% of all participants). Two catheters are most commonly used for right atrial flutter and right ventricular tachycardia/extrasystole ablations (respectively used by 54% and 51% of the overall respondents); a single catheter approach is mostly used for AV node ablation by 67% of the interviewed sample.

Eighty-one percent of the respondents stated to use only the right groin as venous access (left groin: 0.5%; both right and left groins: 18.5%). The femoral venous access is always obtained by ultrasound-guided approach by 37% of respondents while, on the contrary, 28% of respondents never use an ultrasound-guided technique for femoral venous puncture. Around one third of participants (35%) declared to use an ultrasound-guided approach for femoral venous puncture only in selected cases or patients. Most of respondents (84%) never intubate the coronary sinus from the superior jugular/subclavian vein approach while a small minority (3%) does it in all procedures; of note, 13% of participants cannulate the coronary sinus using a jugular approach only in selected
 cases, such as accessory pathway ablations (6%), inability to get a femoral access (4%), atrial
 fibrillation ablation (1%), and AVNRT ablation (1%).

4 Anticoagulation management before EP studies and right-sided ablation procedures

5 Direct oral anticoagulation (DOAC) is commonly interrupted before EP studies and right-sided 6 ablation procedures by 44% of respondents (Figure 2). Among these, 74% stop DOAC therapy 7 within 24 hours before the procedure, 25% stop DOAC therapy 24-48 hours before the procedure 8 and 1% suspend the DOAC therapy more than 48 hours before the procedure (Figure 2). Among 9 respondents who commonly stop DOAC therapy, the majority (68%) resumes DOAC therapy on 10 the day of the procedure and 29% on the following day (Figure 2).

11 On the other side, vitamin K antagonists (VKA) are interrupted before EP studies and right-sided 12 ablation procedures by 34% of respondents (Figure 3). Among the latter, 37% stop VKA therapy 13 within 24 hours from the procedure, 44% 24-48 hours before the procedure and 19% suspend VKAs 14 for more than 48 hours before the procedure (Figure 3). Of note, the heparin bridging therapy is 15 adopted by 29% of respondents who stop VKAs before the procedure (Figure 3).

16 Anticoagulation management during EP studies and right-sided ablation procedures

The majority of respondents (72%) never administer intravenous (i.v.) heparin during EP studies (Figure 4); 16% administer a fixed dose of i.v. heparin, 9% a weight-adjusted dose of i.v. heparin and the remaining 3% an ACT-directed dose of i.v. heparin. Similarly, most of the respondents (63%) do not administer i.v. heparin during right-sided supraventricular tachycardia ablations (Figure 4); the remaining physicians use a fixed dose of i.v. heparin (26%), a weight-adjusted dose of i.v. heparin (9%) or ACT-directed dose of i.v. heparin (2%).

Of note, the majority of participants (69%) irrigates long sheath introducers during EP studies and right-sided ablation procedures; among them, 80% irrigate with heparin saline solution and the remaining 20% use a normal saline infusion.

26

1 Femoral venous access and post-procedural management

2 After the procedures, bed rest is recommended for less than 4 hours by 12% of respondents, for 4-6 3 hours by 70% of respondents, and for more than 6 hours by 18% of respondents. Participants were 4 also asked about the type of venous access site closure and management: manual compression was declared as the most common way to achieve the venous access closure (59%); Z-suture was 5 preferred by 39% of respondents. Vascular closure devices (Perclose ProglideTM and Angio-Seal) 6 are used by 2% of participants. Among respondents who apply Z-suture in the femoral venous 7 access, 7% of them remove it within 4 hours, 14% of them 4-6 hours later, 9% of them cut the 8 9 suture 6 hours later on the same day and, most of them (70%), remove the Z-suture the day after or even later. 10

Of note, compression dressings are routinely applied after the procedure by 25% of respondents.
Among the latter, 14% remove the compression dressing within 4 hours, 24% keep the dressing for
4 hours, 42% for 6 hours and 20% for more than 6 hours.

Finally, nearly half of respondents (46%) routinely remove the venous sheaths while aspiratingblood with a syringe to pull out possible clots or thrombi.

Patients are commonly discharged at home on the day of the diagnostic EP study by 36% of 16 respondents (53% of respondents never discharge the same day). The remaining 11% of them 17 discharge the patient on the same day only if the procedure is performed in the morning. In case of 18 AVNRT ablation, 74% of respondents never discharge patients on the same day; on the other hand, 19 20 17% of physicians always discharge in the evening after the procedure and a further 9% of respondents discharge the patient on the same day only if the procedure is performed in the 21 morning. Similarly, with right-sided accessory pathway ablation, 75% of respondents never 22 23 discharge patients on the same day; on the contrary, 15% of respondents always discharge in the evening after the procedure and the remaining 10% discharge only if the procedure is performed in 24 the morning. 25

In case of right atrial tachycardia and right atrial flutter ablations, 77% and 75%, respectively, of respondents never discharge patients on the same day. When ablation of premature ventricular contraction or ventricular tachycardia in the right ventricle are performed, 82% of respondents never discharge patients on the same day; conversely, only 7% of respondents always discharge in the evening after the procedure.

6 VTE prevention strategies after EP studies and right-sided ablation procedures

As shown in Figure 5A, medical prophylaxis for VTE following EP studies and right-sided ablations, during the hospital stay, is never done by 2/3 of physicians (67%); on the other hand, 17% of respondents routinely prescribe low-molecular-weight heparin (LMWH) after the procedures and a further 14% routinely prescribe aspirin. After discharge, medical prophylaxis for VTE is never done by 76% of physicians; of note, 17% of respondents routinely prescribe aspirin after discharge and a small minority usually prescribes LMWH and oral anticoagulation (respectively, 4% and 3%) (Figure 5B).

Overall, 33% of the respondents routinely prescribe VTE prophylaxis early after the EP studies and right-sided ablations and 24% of the respondents commonly prescribe VTE prophylaxis after discharge. If a pharmacological prophylaxis for VTE is prescribed, the mean duration is for 29±21 days (median 29.5 days, interquartile range 14 to 30 days). When aspirin is used as VTE prophylaxis, the mean duration of the therapy is for 32±17 days (median 30 days, IQR 27; 30); medical prophylaxis with LMWH is prescribed for a median duration of 6 days (IQR 3;75).

Most of the physicians (69%) do not change their strategy to prevent VTE based on the presence of specific risk factors. However, 31% of respondents report to change their strategy to prevent VTE according to specific risk factors; the latter ones are known, previous episodes of VTE (40%), concomitant therapy with oral contraceptives (16%), obesity (12%), smoking habit (5%), female gender (5%), known thrombophilic disease or hypercoagulable condition (5%). Of note, 25 out of 184 respondents (13%) experienced within the last year at least one DVT related
to right-sided ablation or EP study. In addition, 9% (n=16) of respondents also stated that they
experienced within the last year at least one PE related to right-sided ablation or EP study.

4 The analysis of specific subgroups (Northern vs Southern Europe, fully trained EPs vs junior/senior fellows) did not show significant differences in terms of intra-procedural i.v. heparin and VTE 5 prophylaxis. In particular, a virtual line was drawn throughout the Alps in order to divide Europe 6 into Northern and Southern Europe. Between 129 respondents from Northern Europe and 115 7 respondents from Southern Europe, no differences were found in terms of administration of i.v. 8 9 heparin during EP studies (respectively, 33% vs 23%; p=0.1) and right-sided ablations (39% vs 34%, p=0.4). No differences were also found in terms of VTE prophylaxis: 36% of participants 10 from Northern Europe versus 31% of participants from Southern Europe routinely prescribe VTE 11 prophylaxis after the procedure (p=0.4). Similarly, VTE prophylaxis after discharge was commonly 12 prescribed by 26% of respondents from Northern Europe compared with 23% of respondents from 13 Southern Europe (p=0.6). Between 178 fully trained EPs and 66 junior/senior fellows, no 14 differences were found in terms of administration of i.v. heparin during EP studies (respectively, 15 31% vs 23%; p=0.2) and right-sided ablations (42% vs 29%, p=0.1). No differences were also 16 found in terms of VTE prophylaxis: 34% of fully trained EPs versus 30% of junior/senior EP 17 fellows routinely prescribe VTE prophylaxis after the procedure (p=0.5). Similarly, VTE 18 prophylaxis after discharge was commonly prescribed by 25% of respondents from Northern 19 20 Europe compared with 21% of respondents from Southern Europe (p=0.5).

22 Discussion

21

23 The main findings of the present survey are listed in the Table 1.

24 In the last three decades, invasive EP studies and catheter ablation have become standard of care in

the diagnosis and treatment of cardiac arrhythmias¹⁶⁻¹⁸. Although catheter ablation has a high yield-

26 to-complication ratio, the occurrence of venous thromboembolic complications is not neglectable.

As reported by previous studies, the evidence of asymptomatic DVT following catheter ablation is
high, ranging between 0 and 16%⁷. Nevertheless, the incidence of symptomatic DVT is much lower
(0.5–0.8%)^{1,13,19}. Three different mechanisms can be identified for the development of DVT/PE: 1)
venous stasis and inflammation at the puncture site; 2) thrombosis due to radiofrequency ablation;
3) groin bandage and immobility after procedures leading to venous stasis.

6 The Multicenter European Radiofrequency Survey (MERFS)¹, the largest cohort including 4398 7 patients referred for catheter ablation of supraventricular or ventricular tachycardias, showed that 8 DVTs were identified in 0.5% of and the risk of embolic events following right-sided procedures 9 was extraordinarily uncommon (0.06%). However, the true rate of VTE is surely underestimated as 10 a systematic search of thromboembolic complications is not routinely done after procedures; as a 11 matter of fact, asymptomatic rate of VTE has been reported to be much higher^{11,12}.

12 Chen et al¹¹ reported an incidence of 17.6% for the development of asymptomatic, non-occlusive 13 DVTs after EP studies using multiple venous sheaths. Repeat ultrasonography at one week 14 documented regression of the non-occlusive DVTs in 92% of cases. A similar incidence of 15 asymptomatic thrombosis (20%) was reported by Tiroke et al¹² despite the use of i.v. heparin.

Currently, there are no guidelines or consensus documents about the management of EP studies and 16 right-sided ablations in terms of anticoagulation and VTE prevention before, during and after the 17 procedures. Of note, this survey shows that i.v. heparin is never administered by the majority of 18 operators during EP studies or right-sided ablations (respectively 72% and 63% of participants). A 19 20 Canadian survey recently reported similar findings⁵. Generally, most of centers do not administer 21 intra-procedural i.v. heparin during EP studies or right-sided ablation procedures, probably because the thrombotic risk is deemed to be largely overcome by the hemorrhagic risk. However, although 22 23 venous thromboembolic complications are infrequent, they might potentially be life-threatening such as in case of PE. As VTE prophylaxis after right-sided EP procedures, some operators 24 prescribe aspirin (oral, 50–150 milligrams) for a period of 1–3 months following catheter ablation; 25 on the other hand, some physicians commonly use heparin during the procedure and a few days 26

after to prevent venous thromboembolism⁷. Although a discrete amount of operators gives aspirin
for VTE prevention after right-sided EP procedures, there is no clear evidence supporting aspiring
for prevention of DVT and PE. Low molecular weight heparin represents the cornerstone for
prevention of DVT and PE following major surgery and invasive procedures²⁰.

However, a recent multicenter, randomized, noninferiority trial compared enoxaparin 30 mg twice 5 daily with aspirin 81 mg twice daily, as thromboprophylaxis in 12'211 patients with either 6 surgically treated extremity fractures or with any pelvic or acetabular fracture. This study showed 7 that aspirin was noninferior to LMWH in preventing death and was associated with a low 8 incidences of DVT and PE and low 90-day mortality²¹. On the other hand, a recent and large meta-9 analysis concluded that aspirin was inferior when compared with other anticoagulants in VTE-10 related orthopedic major surgery²². Therefore, the role of aspirin for VTE prevention after surgery 11 and invasive procedures is controversial, and needs more evidence. 12

The present survey shows that systematic prophylaxis for VTE following EP studies and right-sided 13 ablations is never done – during the hospital stay - by two-thirds of physicians (67%) and - after the 14 discharge - prophylaxis for VTE is not considered by three-quarters (76%) of respondents. Nearly a 15 fifth of the overall respondents (17%) routinely prescribes aspirin after the discharge. This EHRA 16 survey confirms lack of systematic DVT prophylaxis following right sided EP procedures and 17 ablations. Although the ultrasound-guided approach has been shown to significantly reduce groin 18 complications compared with conventional "blind" puncture technique²³⁻²⁵, a considerable amount 19 20 of electrophysiologists (28%) still never use echo-color-doppler to puncture femoral veins in EP 21 studies and right-sided ablation and 35% use it only in selected cases.

In patients under direct oral anticoagulation before the procedure, this therapy is usually not interrupted by most of the operators (56%); in case of VKA, most of respondents did not suspend the therapy before the procedure (66%). Among one third of respondents who usually stop VKAs, a minority (29%) is still replacing oral anticoagulation with heparin before the procedure (the socalled "bridging heparin therapy"). However, bridging with LMWH has been clearly shown to be associated with higher incidence of groin hematoma/bleeding compared to continuation of VKA in
left-sided procedures and device implantation procedures^{26,27}. With the current evidence of a lower
hemorrhagic complication rate with uninterrupted VKA therapy, the bridging strategy should be
clearly abandoned also in EP and right-sided ablation procedures.

A very interesting strategy is commonly adopted by one third of participants who tailor their behavior according to the presence of specific risk factors such as previous episodes of VTE, concomitant therapy with oral contraceptives, obesity, smoking habit, female gender, known hypercoagulable conditions. In addition, an accurate sheath management with frequent flushing or continuous irrigation, especially with heparin saline solution, might help to minimize the risk VTE¹⁰. In our survey, more than two thirds of participants (69%) commonly irrigate the femoral sheaths and, among them, 80% routinely use heparin saline solution.

In our survey only 25% of respondents regularly used compression dressings, with a variable 12 duration of application that commonly does not exceed 6 hours (80% of respondents used to remove 13 compression dressings no more than 6 hours later). There was relative homogeneity among the 14 prescribed duration of bed rest after EP procedures, with most of physicians (82%) recommending 6 15 hours or less. A potential preventive strategy to avoid thromboembolic complications is the "same-16 day discharge"^{28,29}. The present survey showed that this strategy is predominantly used in case of 17 diagnostic EP studies. As a matter of fact, an early mobilization and a quick resumption to the 18 routine daily life may significantly reduce the blood flow stasis and potentially reduce procedure-19 related VTE complications. 20

Of note, 13% of participants stated they had experienced at least one DVT related to right-sided ablation or EP study within the last year in their Centre. Likewise, 9% of respondents declared at least one PE related to right-sided ablation or EP study within the last year. This data might be strongly limited by a possible overestimation due to the possibility of more respondents coming from the same Centre.

26 By the way, our data confirm that the incidence of DVT/PE is rather low.

1 Larger, multicentric, prospective and randomized studies are needed to identify which, if any, of

2 these post-procedural factors may affect the development of post-procedural VTE.

3 Limitations

The present survey has limitations attributed to target respondents and questionnaire design. The survey included a limited number of selected physicians and participation was completely voluntary, therefore being prone to selection bias. Moreover, junior EP fellows are included in the present survey (18% of all respondents); as they might tend to follow or reproduce their Center protocols or Senior colleagues' behaviour, this might represent a potential limitation.

9 Being a physician-based survey, physicians belonging to same EP centers might have answered10 leading to a possible overestimation of some periprocedural management strategies.

11 Italy and Germany represented about 40% of the 33 involved European countries.

12 Local vascular complications have not been collected by the questionnaire.

13 Conclusions

The present survey shows that only a minority of operators routinely gives intraprocedural intravenous heparin and prescribes VTE prophylaxis after right-sided EP procedures. Compared to left sided procedures like AF ablation, there are no consistent systematic antithrombotic management strategies. Thus, additional studies and guidelines or consensus statements are needed in order to standardize VTE prevention strategies throughout EP centers.

19

20 Acknowledgements

The production of this document is under the responsibility of the Scientific Initiatives Committee of the European Heart Rhythm Association: Julian K.R. Chun (Chair), Sergio Castrejon (Co-Chair), Ante Anic, Giulio Conte, Piotr Futyma, Andreas Metzner, Federico Migliore, Giacomo Mugnai, Laura Perrotta, Rui Providencia, Sergio Richter, Laurent Roten, and Arian Sultan. The authors acknowledge the EHRA Scientific Research Network centers participating in this survey. A list of these centers can be found on the EHRA website.

1	Data availability	statement:	not applicable.
T	Data availability	statement.	not applicable.

2

3 **References**

4	1.	Hindricks G. The Multicenter European Radiofrequency Survey (MERFS): Complications
5		of radiofrequency catheter ablation of arrhythmias. Eur Heart J 1993;14: 1644–1653.
6	2.	Alizadeh A, Yazdi AH, Kafi M, Rad MA, Moradi M, Emkanjoo Z. Predictors of local
7		venous complications resulting from electrophysiological procedures. Cardiol J 2012; 19:
8		15-19
9	3.	Jacobs CE, Pinzon MM, Orozco J, Hunt PJ, Rivera A, McCarthy WJ. Deep venous
10		thrombosis after saphenous endovenous radiofrequency ablation: is it predictable? Ann Vasc
11		Surg 2014; 28:679-685
12	4.	Burstein B, Barbosa RS, Kalfon E, Joza J, Bernier M, Essebag V. Venous thrombosis after
13		electrophysiology procedures: a systematic review. Chest 2017; 152: 574-586
14	5.	Burstein B, Barbosa RS, Samuel M, Kalfon E, Philippon F, Birnie D, et al. Prevention of
15		venous thrombosis after electrophysiology procedures: a survey of national practice. J Interv
16		Card Electrophysiol 2018; 53: 357-363
17	6.	Davutoglu V, Kervancioglu S, Dinckal H, Soydinc S, Turkmen S, Akdemir I, et al. High
18		incidence of occult femoral vein thrombosis related to multiple venous sheath during
19		electrophysiological studies. Heart 2004; 90:1061-1062
20	7.	Li L, Zhang BJ, Zhang BK, Ma J, Liu XZ, Jiang SB. Prevention and treatment of lower limb
21		deep vein thrombosis after radiofrequency catheter ablation: results of a prospective active
22		controlled study. Sci Rep 2016; 6: 28439
23	8.	Moubarak G, Bonhomme S, Vedrenne G, Bouleti C, Ollitrault J, Priollet P, et al. Femoral
24		vein thrombosis after right-sided electrophysiological procedures. J Interv Card
25		Electrophysiol 2013; 38: 155-158

1	9. Saunderson C, Hickman S, Wilkinson E, Tayebjee M. Current venous thromboembolism
2	prevention practices following endovascular electrophysiological procedures in the UK: a
3	retrospective study. Sultan Qaboos Univ Med J 2018; 18: e374-e378
4	10. Tompkins C. Venous thrombosis following femoral venous access for electrophysiology
5	studies: an on-going challenge. Cardiol J 2012; 19: 1-3
6	11. Chen JY, Chang KC, Lin YC, Chou HT, Hung JS. Safety and outcomes of short-term
7	multiple femoral venous sheath placement in cardiac electrophysiology study and
8	radiofrequency catheter ablation. Jpn Heart J 2004; 45: 257–264
9	12. Tiroke A, Stracke L, Seeger M, Lins M, Simon R. Thrombosis after EP study: A frequent
10	complication? Heart Rhythm 2005; 2: S114
11	13. Green TO, Huang SK, Wagshal AB, Mittleman RS, Pires LA, Mazzola F, et al.
12	Cardiovascular complications after radiofrequency catheter ablation of supraventricular
13	tachyarrhythmias. Am J Cardiol 1994; 74: 615–617
14	14. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017
15	HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical
16	ablation of atrial fibrillation: Executive summary. Europace. 2018;20:157-208.
17	15. Wazni OM, Rossillo A, Marrouche NF, Saad EB, Martin DO, Bhargava M, et al. Embolic
18	events and char formation during pulmonary vein isolation in patients with atrial fibrillation:
19	impact of different anticoagulation regimens and importance of intracardiac echo imaging. J
20	Cardiovasc Electrophysiol 2005; 16:576-581
21	16. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al. 2019
22	ESC guidelines for the management of patients with supraventricular tachycardia. Eur Heart
23	J 2020; 41:655-720
24	17. Boersma L, Andrade JG, Betts T, Duytschaever M, Pürerfellner H, Santoro F, et al. Progress
25	in atrial fibrillation ablation during during 25 years of Europace journal. Europace 2023;
26	25(9): euad244

1	18. Natale A, Zeppenfeld K, Della Bella P, Liu X, Sabbag A, Santangeli P, et al. Twenty-five
2	years of catheter ablation of ventricular tachycardia: a look back and a look forward.
3	Europace 2023; 25(9): euad225
4	19. Epstein MR, Knapp LD, Martindill M, Lulu JA, Triedman JK, Calkins H, et al. Embolic
5	complications associated with radiofrequency catheter ablation. Atakr Investigator Group.
6	Am J Cardiol 1996; 77: 655-658
7	20. Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, et al. American
8	Society of Hematology 2019 Guidelines for management of venous thromboembolism:
9	prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019;
10	3:3898-3944
11	21. Major Extremity Trauma Research Consortium (METRC); O'Toole RV, Stein DM, O'Hara
12	NN, Frey KP, Taylor TJ, et al. Aspirin or low-molecular-weight heparin for
13	thromboprophylaxis after a fracture. N Engl J Med 2023; 388:203-213
14	22. Liu HZ, Liang J, Hu AX. The efficacy and safety of aspirin in preventing venous thrombosis
15	in major orthopedic surgery: an updated meta-analysis of randomized controlled trials.
16	Medicine (Baltimore) 2023; 102: e35602
17	23. Ding WY, Khanra D, Kozhuharov N, Shaw M, Luther V, Ashrafi R, et al. Incidence of
18	vascular complications for electrophysiology procedures in the ultrasound era: a single-
19	centre experience over 10,000 procedures in the long term. J Interv Card Electrophysiol
20	2023;66:693-700
21	24. Stroker E, de Asmundis C, Kupics K, Takarada K, Mugnai G, De Cocker J, et al. Value of
22	ultrasound for access guidance and detection of subclinical vascular complications in the
23	setting of atrial fibrillation cryoballoon ablation. Europace 2019; 21: 434-439
24	25. Kupo P, Riesz TJ, Saghy L, Vamos M, Bencsik G, Makai A, et al. Ultrasound guidance for
25	femoral venous access in patients undergoing pulmonary vein isolation: a quasi-randomized
26	study. J Cardiovasc Electrophysiol 2023; 34:1177-1182

1	26. Kwak JJ, Pak HN, Jang JK, Kim SK, Park JH, Choi JI, et al. Safety and convenience of
2	continuous warfarin strategy during the periprocedural period in patients who underwent
3	catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21: 620-625

- 4 27. Hakalahti A, Uusimaa P, Ylitalo K, Pekka Raatikainen MJ. Catheter ablation of atrial
 5 fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 2011;
 6 13:640-645
- Z8. Konig S, Andrade JG, Bollmann A. Administrative data confirm safety of same-day
 discharge following catheter ablation of atrial fibrillation: all good or is there a fly in the
 ointment? Europace 2022; 24:701-702
- 29. Jimenez-Candil J, Hernandez J, Cruz Galban A, Blanco F, Morinigo JL, Sanchez Garcia M,
 et al. Clinical and economic outcomes of a systematic same-day discharge program after
 pulmonary vein isolation: comparison between cryoballoon versus radiofrequency ablation.
 Europace 2023 [Online ahead of print]

14

15 Figure legends

16 **Figure 1:** geographical map showing the distribution of the main responders across Europe.

Figure 2: the picture illustrates the management of direct oral anticoagulants before EP studies andright-sided ablation procedures.

Figure 3: the picture illustrates the management of vitamin K antagonists before EP studies andright-sided ablation procedures.

21 Figure 4: on the left – the graphic shows how many physicians administer intravenous heparin

22 during EP studies; on the right – the picture illustrates how many operators administer intravenous

23 heparin during right-sided ablations.

- **Figure 5:** A the pie chart shows the proportion of physicians who gives VTE prophylaxis during
- 25 the hospital stay and the type of medical prophylaxis; \mathbf{B} the pie chart illustrated the rate of

1 physicians who commonly prescribes VTE prophylaxis after the discharge and the type of medical 2 prophylaxis.

3

4 Graphical Abstract Legend: EP: electrophysiological; ACT: activated clotting time; i.v.: intra-

venous; VTE: venous thromboembolism; UF: unfractionated; lmwh: low molecular weight heparin. 5

6

7 Table 1. Key messages

The echo-guided approach for femoral venous access is routinely adopted in roughly one third of respondents

The right groin is usually chosen as the only access site

Intravenous heparin is adopted by, respectively, 28% and 37% of participants during EP studies and right-sided ablations

Before the procedure: in patients on VKA "heparin – bridging" is still standard of care in 29%

and DOACs are interrupted by 44% of respondents

After the procedure/in-hospital: 33% of participants routinely prescribe VTE prophylaxis after

the EP studies and right-sided ablations (mostly LMWH, 17%, and aspirin, 14%)

After hospital discharge: 25% of respondents commonly prescribe VTE prophylaxis even after the discharge (mostly aspirin) for a median duration of 30 days

- EP: electrophysiological; VKA: vitamin K antagonists; DOAC: direct oral anticoagulants; VTE: venous 8
- 9 thromboembolisms; LMWH: low molecular weight heparin.



When patients are taking VKAs, do you stop them before the procedure?

If yes, how long before the procedure do you stop VKAs?

If yes, do you use the "heparin bridging" strategy?



VTE prophylaxis during the hospital stay



Venous Thromboembolism in right-sided EP procedures

9% of respondents experienced at least one pulmonary embolism related to right-sided EP procedures in the last year

